Drugs / anti-CD19 anti-CD20 Bispecific CAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03271515 | Mar 2021 → Mar 2022 | leukemia, lymphoma | Beijing Doing Biomedical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-CD19 anti-CD20 Bispecific CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03271515 ↗ |
| Modality | Cell therapy | “Advanced Therapy Investigational Medicinal Product named CD19 CD20 Chimeric Antigen Receptor (CAR) T-cells” NCT03271515 ↗ |
| Route | Other | “patients accept transfusion of anti-CD19 anti-CD20 Bispecific CAR-T cells.” NCT03271515 ↗ |